This landscape-changing technology has the potential to be used to manage some of healthcare’s most challenging diseases quickly and efficiently.
When detected early by PSMA PET scans, recurrent prostate cancer can be treated through a targeted approach with stereotactic body radiation therapy, surgery and/or systemic therapy.
Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosingand provides effective and sustained LDL-C reduction.
Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal.
This treatment appears to show benefits very quickly, while traditional anti-depressants typically take two to four weeks to have a significant effect.
A first-in-class medication specifically targets heart muscle to reduce abnormal contractions caused by genetic variants that put the heart into overdrive.
A new group of non-hormonal drugs, called NK3R antagonists, have emerged as a viable alternative to hormone therapy.
The technology uses implanted electrodes to collect movement signals from the brain and decode them into movement commands. Shown to restore voluntary motor impulses in patients with severe paralysis.
Using AI algorithms, the tool detects several key risk factors in real time by monitoring patients’ electronic medical records as physicians input information.
Predictive analytics equip providers with the key that could open the door to preventing hypertension and many other diseases.